Head-to-head · WeighScore
OrderlyMeds vs Vitara RX
By GLP-1 ScorecardUpdated
Score comparison
Vitara RX has the higher recorded score — 86/100 to 67/100.
Vitara RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Sub-$100 semaglutide and $149 tirzepatide — both molecules, verified and nationwide.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | OrderlyMeds | Vitara RX |
|---|---|---|
| WeighScore | 67/100 | 86/100 |
| Grade | C | B |
| Site position | #191 | #11 |
| Semaglutide | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) | $99/mo |
| Tirzepatide | $299/mo (compounded) | $149/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #191 · C
FDAWarning letter issued to OrderlyMeds LLC dba OrderlyMeds in June 2026. See the FDA warning-letter database.
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
What to consider
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- FDA issued OrderlyMeds LLC dba OrderlyMeds a warning letter in June 2026; the letter is public in FDA's warning-letter database
Site position #11 · B
Strengths
- $99 sema / $149 tirz — bottom-quartile pricing
- Both molecules, all 50 states
- LegitScript-verified
What to consider
- Injection-only, no oral route
- Labs/monitoring not detailed
- Newer, thinner track record
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.